Artis BioSolutions, an advanced therapies company in San Diego, established new synthetic DNA manufacturing capabilities in Boston utilizing Bilbao, Spain-based Syngoi Technologies’ proprietary enzymatic platform. This expansion strategically extends Artis’ regional capabilities, integrating with their advanced therapy development and GMP manufacturing facility in Watertown, MA, to deliver efficient solutions for its global customer base, according to Brian Neel, CEO of Artis.
“Artis was founded to more effectively provide platforms and capabilities that drug developers require to bring next-generation medicines to patients,” continued Neel. “Establishing U.S.-based synthetic DNA manufacturing is a pivotal step in the evolution of the Artis platform and reinforces our mission to integrate specialized technologies—from synthetic DNA through GMP manufacturing—into a seamless, end-to-end offering.
By offering Syngoi Technologies at our U.S. site, we are delivering a much-needed capability to our customers focused on early development through clinical manufacturing while strengthening our global operational resilience.”
By operating production hubs on both sides of the Atlantic, Artis says it provides enhanced service continuity and a more secure supply chain for its global partners. This dual-sourcing strategy across the U.S. and Europe reduces lead times and logistics costs while mitigating the geopolitical and operational risks associated with single-region sourcing, points out a company spokesperson, states a company official, who adds that this expansion also positions Artis’ specialized technical expertise in immediate proximity to its key clients and strategic partners in the U.S. market.
